|
Synonyms: Atenenol®
alprenolol is an approved drug
Compound class:
Synthetic organic
Comment: The approved drug alprenolol is a racemic mixture of the R and S isomers. We show the non-stereo structure to represent the mixture.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor. Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733] |
|
2. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144 (3): 317-22. [PMID:15655528] |
|
3. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. PLoS ONE, 5 (11): e15487. [PMID:21152092] |
|
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077] |
|
5. Baker JG, Adams LA, Salchow K, Mistry SN, Middleton RJ, Hill SJ, Kellam B. (2011)
Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors. J Med Chem, 54 (19): 6874-87. [PMID:21870877] |
|
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341] |
|
7. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666] |
|
8. Baker JG, Hall IP, Hill SJ. (2004)
Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol, 65 (4): 986-98. [PMID:15044629] |
|
9. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025)
Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor. Mol Pharmacol, 107 (11): 100081. [PMID:41289653] |
|
10. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol, 112 (3): 911-9. [PMID:7921620] |
|
11. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004)
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417] |
|
12. Strosberg AD. (1997)
Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260] |